Evidence map›Paper›PMID 40382406›Full record

ArticleScientific reports2025

Computational exploration of Eucommia ulmoides flavonoids as potential RANKL inhibitors via molecular docking and dynamics simulations.

Xiaofei Zhang, Lixia Zhang, Dan Li, Qi Wang, Libin Wang, Ziqi Zheng, Yun Xie

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiaofei Zhang *Department of Laboratory Medicine, Northwest Women's and Children's Hospital, 1616 Yanxiang Road, Xi'an, 710061, Shaanxi, China.
Lixia Zhang *Department of Clinical Laboratory, Shaanxi Provincial People's Hospital, Xi'an, China.
Dan LiDepartment of Laboratory Medicine, Northwest Women's and Children's Hospital, 1616 Yanxiang Road, Xi'an, 710061, Shaanxi, China.
Qi WangDepartment of Clinical Laboratory, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Libin WangDepartment of Laboratory Medicine, Northwest Women's and Children's Hospital, 1616 Yanxiang Road, Xi'an, 710061, Shaanxi, China.
Ziqi ZhengCollege of Life Sciences, Northwest University, 229 North Taibai Road, Xi'an, Shaanxi, 710069, People's Republic of China.
Yun XieDepartment of Laboratory Medicine, Northwest Women's and Children's Hospital, 1616 Yanxiang Road, Xi'an, 710061, Shaanxi, China. xieyunhero@sina.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoporosis, characterized by excessive osteoclast activation, is mediated through the RANKL/RANK/OPG signaling axis. While flavonoids from Eucommia ulmoides (EU) have demonstrated anti-osteoclastogenic activity, their atomic-level mechanisms remain elusive. Here, we investigated six EU-derived flavonoids (cyrtominetin, quercetin, syringetin, genistein, ombuin, and kaempferol) targeting RANKL using integrated computational approaches. Molecular docking revealed strong binding affinities (Total_Score > 4.0) for all compounds, with cyrtominetin exhibiting the highest affinity (-50.205 kJ/mol via MM-PBSA), primarily through hydrogen bonds with Gly178, His180, Lys181, and Asn295. Moreover, most flavonoids interacted with RANKL by forming strong hydrogen bonds with Gly178 and Asn295, exhibiting higher binding affinity that was identified as essential for the activity. All-atom molecular dynamics simulations (100 ns) confirmed complex stability, demonstrating: low RMSD fluctuations (< 4.0 Å) and compact Rg values (16.0-17.0 Å). Notably, binding free energy decomposition identified both electrostatic and van der Waals contributions as critical for stabilization. These results identify cyrtominetin as a promising lead compound for RANKL inhibition, providing structural insights for designing flavonoid-based therapeutics against osteoporosis.

Indexed as

EucommiaceaeFlavonoidsMolecular Docking SimulationRANK LigandHumansHydrogen BondingMolecular Dynamics SimulationProtein BindingFlavonoidsRANK LigandFlavonoidsMolecular dockingMolecular dynamicsOsteoporosisRANKL

Identifiers

PMID40382406
PMCPMC12085681

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.